medigraphic.com
ISSN 0016-3813 (Print)

2006, Number 5

<< Back Next >>

Gac Med Mex 2006; 142 (5)

Human defensins: prophilaxis and therapy against HIV?

Prado-Montes de Oca E

Language: Spanish
References: 26
Page: 431-433
PDF size: 95.51 Kb.


ABSTRACT

Human defensins are endogenous antimicrobial peptides with prophylactic and therapeutic potential against HIV. The ability of defensins to bind the HIV envelope could be exploited to design topic agents that block viral entry into exposed mucosa. Additionally, their capacity to inhibit viral replication, complement system activation, dendritic and memory T cells chemoattraction, together with peptide engineering could bring about new and better antiretroviral drugs. Clinical trials could be demonstrated the efficacy of defensins against HIV in clinical practice.


REFERENCES

  1. Agrawal L, Lu X, Jin Q, Alkhatib G. Anti-HIV therapy: Current and future directions. Curr Pharm Des 2006;12:2031-2055.

  2. Madan RP, Keller MJ, Herold BC. Prioritizing prevention of HIV and sexually transmitted infections: first-generation vaginal microbicides. Curr Opin Infect Dis. 2006;19:49-54.

  3. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005;6:551-557.

  4. Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, et al. Activity of alpha and theta defensins against primary isolates of HIV. J Immunol 2004;173:515-520.

  5. Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La Terra Maggiore GM, et al. Human β-defensins suppress Human Immunodeficiency Virus Infection: potential role in mucosal protection. J Virol 2005;79:14318-14329.

  6. Chang TL, Francois F, Mosoian A, Klotman ME. CAF-mediated Human Immunodeficiency Virus (HIV) type 1 transcriptional inhibition is distinct from adefensin-1 HIV inhibition. J Virol 2003;77:6777-6784.

  7. Prohaszka Z, Nemet K, Csermely P, Hudecz F, Mezo G, Fust G. Defensins purified from human granulocytes bind C1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 of HIV-1. Mol Immunol 1997;34:809-816.

  8. Chang TL, Vargas J Jr, Del Portillo A, Klotman ME. Dual role of alphadefensin-1 in anti-HIV-1 innate immunity. J Clin Invest 2005;115:765-773.

  9. Trabattoni D, Caputo SL, Maffeis G, Vichi F, Biasin M, Pierotti P, et al. Human alpha defensin in HIV-exposed but uninfected individuals. J Acquir Immune Defic Syndr. 2004;35:455-463.

  10. Kuhn L, Trabattoni D, Kankasa C, Semrau K, Kasonde P, Lissoni F, et al. Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr 2005;39:138-142.

  11. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, et al. Betadefensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999;286:525-528.

  12. Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA. Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: high-throughput SNP assays and association with Candida carriage in type 1 diabetics and nondiabetics controls. J Clin Microbiol 2003;41:90-96.

  13. Jang BC, Lim KJ, Paik JH, Kwon YK, Shin SW, Kim SC, et al. Up-regulation of human beta-defensin 2 by interleukin-1 beta in A549 cells: involvement of PI3K, p38 MAPK, JNK, and NF-kappaB. Biochem Biophys Res Commun 2004;320:1026-1033.

  14. Braida L, Boniotto M, Pontillo A, Tovo PA, Amoroso A, Crovella S. A singlenucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-1 infection in Italian children. AIDS 2004;18:1598-1600.

  15. Milanese M, Segat L, Pontillo A, Arraes LC, de Lima Filho JL, Crovella S. DEFB1 gene polymorphisms and increased risk of HIV-1 infection in Brazilian children. AIDS 2006;20:1673-1675.

  16. Weinberg A, Quinones-Mateu ME, Lederman MM. Role of human betadefensins in HIV infection. Adv Dent Res 2006;19:42-48.

  17. Campo J, Perea MA, del Romero J, Cano J, Hernando V, Bascones A. Oral transmission of HIV, reality or fiction? An update. Oral Dis 2006;12:219-228.

  18. Feng Z, Dubyak GR, Lederman MM, Weinberg A. Cutting edge: human beta defensin 3- a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol, 2006;177:782-786.

  19. Tang YQ, Yuan J, Osapay G, Osapay K, Tran D, Miller CJ, et al. A cyclic antimicrobial peptide produced in primate leucocytes by the ligation of two truncated alpha-defensins. Science 1999;286:498-502.

  20. Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, Bristol G, et al. Retrocyclin: a primate peptide that protects cells from infection by T-and M-tropic strains of HIV-1. Proc Natl Acad Sci USA 2002;99:1813-1818.

  21. Wang W, Cole AM, Hong T, Waring AJ, Lehrer RI. Retrocyclin, an antiretroviral theta-defensin, is a lectin. J Immunol 2003; 170:4708-4716.

  22. Gallo SA, Wang W, Rawat SS, Jung G, Waring AJ, Cole AM, et al. Thetadefensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 2006;281:18787-18792.

  23. Linzmeier RM, Ganz T. Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. Genomics 2005;86:423-430.

  24. Ganz T. Versatile defensins. Science 2002;298:977-979.

  25. Espona M, Ferrández O, Grau S, Carmona A. Enfuvirtida: primer fármaco de una nueva familia de antirretrovirales. Farm Hosp 2005;29:375-383.

  26. Yu Q, Lehrer R, Tam JP. Engineered salt-insensitive alpha-defensins with end to end circularized structures. J Biol Chem, 1999;275:3943-3949.




2020     |     www.medigraphic.com